Literature DB >> 24900362

A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.

Behrooz H Yousefi1, Alexander Drzezga1, Boris von Reutern1, André Manook1, Markus Schwaiger1, Hans-Jürgen Wester2, Gjermund Henriksen1.   

Abstract

(18)F-labeled imidazo[2,1-b]benzothiazole ([(18)F]8) was synthesized and evaluated as a tracer for cerebral β-amyloid deposits (Aβ) by means of positron emission tomography (PET). [(18)F]8 exhibits a high affinity to Aβ and suitable brain uptake kinetics combined with a high metabolic stability in the brain. In a double transgenic APP/PS1 mouse model of Alzheimer's disease, we demonstrated a specific uptake of [(18)F]8 in Aβ-containing telencephalic brain regions. The specific binding of [(18)F]8 to Aβ was confirmed by regional brain biodistribution and autoradiography and correlated to immunohistochemistry staining. Analysis of brain sections of APP/PS1 mouse injected with a cocktail of [(18)F]8 and reference compound [(3)H]PiB revealed that the two tracers bind to Aβ plaques in the brain of mouse in a comparable binding pattern. [(18)F]8 represents the first high-contrast PET imaging agent for detection of Aβ plaques in transgenic mouse model of Alzheimer's disease and holds promise for transfer to a clinical evaluation.

Entities:  

Keywords:  18F-labeled tracer for β-amyloid; APP/PS1transgenic mice; Alzheimer's disease; IBT; autoradiography; neuroimaging; positron emission tomography; β-amyloid plaques

Year:  2011        PMID: 24900362      PMCID: PMC4018122          DOI: 10.1021/ml200123w

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  20 in total

Review 1.  Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.

Authors:  D J Selkoe
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Imaging Alzheimer's amyloid.

Authors:  D J Selkoe
Journal:  Nat Biotechnol       Date:  2000-08       Impact factor: 54.908

3.  2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients.

Authors:  Yukitsuka Kudo; Nobuyuki Okamura; Shozo Furumoto; Manabu Tashiro; Katsutoshi Furukawa; Masahiro Maruyama; Masatoshi Itoh; Ren Iwata; Kazuhiko Yanai; Hiroyuki Arai
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

4.  Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils.

Authors:  Andrew Lockhart; Liang Ye; Duncan B Judd; Andy T Merritt; Peter N Lowe; Jennifer L Morgenstern; Guizhu Hong; Antony D Gee; John Brown
Journal:  J Biol Chem       Date:  2004-12-21       Impact factor: 5.157

5.  18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.

Authors:  Hank F Kung; Seok Rye Choi; Wenchao Qu; Wei Zhang; Daniel Skovronsky
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

Review 6.  Biological markers of Alzheimer's disease.

Authors:  W E Klunk
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

7.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

8.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

9.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

10.  Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.

Authors:  Michel Koole; Dewi M Lewis; Christopher Buckley; Natalie Nelissen; Mathieu Vandenbulcke; David J Brooks; Rik Vandenberghe; Koen Van Laere
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

View more
  11 in total

Review 1.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

2.  Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease.

Authors:  André Manook; Behrooz H Yousefi; Antje Willuweit; Stefan Platzer; Sybille Reder; Andreas Voss; Marc Huisman; Markus Settles; Frauke Neff; Joachim Velden; Michael Schoor; Heinz von der Kammer; Hans-Jürgen Wester; Markus Schwaiger; Gjermund Henriksen; Alexander Drzezga
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240

3.  18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases.

Authors:  Timo Grimmer; Kuangyu Shi; Janine Diehl-Schmid; Bianca Natale; Alexander Drzezga; Stefan Förster; Hans Förstl; Markus Schwaiger; Igor Yakushev; Hans-Jürgen Wester; Alexander Kurz; Behrooz Hooshyar Yousefi
Journal:  Mol Psychiatry       Date:  2018-08-17       Impact factor: 13.437

4.  On water catalyst-free synthesis of benzo[d]imidazo[2,1-b] thiazoles and novel N-alkylated 2-aminobenzo[d]oxazoles under microwave irradiation.

Authors:  Narasimharao Mukku; Barnali Maiti
Journal:  RSC Adv       Date:  2020-01-03       Impact factor: 4.036

5.  Reagent-controlled regiodivergent intermolecular cyclization of 2-aminobenzothiazoles with β-ketoesters and β-ketoamides.

Authors:  Irwan Iskandar Roslan; Kian-Hong Ng; Gaik-Khuan Chuah; Stephan Jaenicke
Journal:  Beilstein J Org Chem       Date:  2017-12-18       Impact factor: 2.883

6.  3-Bromo-7-meth-oxy-2-phenyl-imidazo[2,1-b][1,3]benzothia-zole.

Authors:  Alexander S Bunev; Elena V Sukhonosova; Dinara R Syrazhetdinova; Vladimir E Statsyuk; Gennady I Ostapenko; Victor N Khrustalev
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-03-13

7.  FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice.

Authors:  Behrooz H Yousefi; Boris von Reutern; Daniela Scherübl; André Manook; Markus Schwaiger; Timo Grimmer; Gjermund Henriksen; Stefan Förster; Alexander Drzezga; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2015-03-28       Impact factor: 3.138

Review 8.  Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging.

Authors:  Masafumi Shimojo; Makoto Higuchi; Tetsuya Suhara; Naruhiko Sahara
Journal:  Front Neurosci       Date:  2015-12-22       Impact factor: 4.677

9.  Mapping the Binding Interface of PET Tracer Molecules and Alzheimer Disease Aβ Fibrils by Using MAS Solid-State NMR Spectroscopy.

Authors:  Zheng Niu; Riddhiman Sarkar; Michaela Aichler; Hans-Jürgen Wester; Behrooz Hooshyar Yousefi; Bernd Reif
Journal:  Chembiochem       Date:  2020-05-19       Impact factor: 3.164

Review 10.  PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape.

Authors:  Bright Chukwunwike Uzuegbunam; Damiano Librizzi; Behrooz Hooshyar Yousefi
Journal:  Molecules       Date:  2020-02-21       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.